Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Javle M, et al. Among authors: porter d. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28. J Clin Oncol. 2018. PMID: 29182496 Free PMC article. Clinical Trial.
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Nogova L, et al. Among authors: porter d. J Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870574 Free PMC article. Clinical Trial.
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF. Pal SK, et al. Among authors: porter d. Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30. Cancer Discov. 2018. PMID: 29848605 Free PMC article.
Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen receptor-modified T cell therapy.
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Maillie L, et al. Among authors: porter dl. Transplant Cell Ther. 2025 Jan 21:S2666-6367(25)00912-1. doi: 10.1016/j.jtct.2025.01.884. Online ahead of print. Transplant Cell Ther. 2025. PMID: 39848443
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, Hwang WT, Li Y, Leskowitz RM, Farrelly O, Karar J, Christensen S, Barber-Rotenberg J, Gaymon A, Aronson N, Bernstein W, Melenhorst JJ, Roche AM, Everett JK, Zolnoski SA, McFarland AG, Reddy S, Petrichenko A, Cook EJ, Lee C, Gonzalez VE, Alexander K, Kulikovskaya I, Ramírez-Fernández Á, Minehart JC, Ruella M, Gill SI, Schuster SJ, Cohen AD, Garfall AL, Shah PD, Porter DL, Maude SL, Levine BL, Siegel DL, Chew A, McKenna S, Lledo L, Davis MM, Plesa G, Herbst F, Stadtmauer EA, Tebas P, DiNofia A, Haas A, Haas NB, Myers R, O'Rourke DM, Svoboda J, Tanyi JL, Aplenc R, Jacobson JM, Ko AH, Cohen RB, June CH, Bushman FD, Fraietta JA. Jadlowsky JK, et al. Among authors: porter dl. Nat Med. 2025 Jan 20. doi: 10.1038/s41591-024-03478-6. Online ahead of print. Nat Med. 2025. PMID: 39833408
A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques.
Zumbrun EE, Garvey CB, Wells JB, Lynn GC, Van Tongeren SA, Steffens JT, Wetzel KS, Wetzel DL, Esham HL, Garza NL, Lee ED, Scruggs JL, Rossi FD, Brown ES, Weidner JM, Gomba LM, O'Brien KA, Jay AN, Zeng X, Akers KS, Kallgren PA, Englund E, Meinig JM, Kugelman JR, Moore JL, Bloomfield HA, Norris SL, Bryan T, Scheuerell CH, Walters J, Mollova N, Blair C, Babusis D, Cihlar T, Porter DP, Singh B, Hedskog C, Bavari S, Warren TK, Bannister R. Zumbrun EE, et al. Among authors: porter dp. Viruses. 2024 Dec 18;16(12):1934. doi: 10.3390/v16121934. Viruses. 2024. PMID: 39772240 Free PMC article.
DDX50 cooperates with STAU1 to effect stabilization of pro-differentiation RNAs.
Miao W, Porter DF, Siprashvili Z, Ferguson ID, Ducoli L, Nguyen DT, Ko LA, Lopez-Pajares V, Srinivasan S, Hong AW, Yang YY, Cao Z, Meyers RM, Meyers JM, Tao S, Wang Y, Khavari PA. Miao W, et al. Among authors: porter df. Cell Rep. 2025 Jan 6;44(1):115174. doi: 10.1016/j.celrep.2024.115174. Online ahead of print. Cell Rep. 2025. PMID: 39764852 Free article.
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Rowe M, et al. Among authors: porter d. Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371. Online ahead of print. Eur J Haematol. 2024. PMID: 39726154
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
Rodriguez L, Lee HW, Li J, Martin R, Han D, Xu S, Moshiri J, Peinovich N, Camus G, Perry JK, Hyland RH, Porter DP, Abdelghany M, Götte M, Hedskog C. Rodriguez L, et al. Among authors: porter dp. Antimicrob Agents Chemother. 2024 Dec 19:e0123824. doi: 10.1128/aac.01238-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39699245 Free article.
1,871 results